For more on David Nierengarten and Jeffrey La Rosa’s comments: Bluebird prices gene therapy in Europe at $1.8M over 5 years
David Nierengarten: Zynteglo’s Pricing Model Could Create ‘Air Gaps’ in the Company’s Cash Flow

For more on David Nierengarten and Jeffrey La Rosa’s comments: Bluebird prices gene therapy in Europe at $1.8M over 5 years